Details
Stereochemistry | ACHIRAL |
Molecular Formula | C10H15N.ClH |
Molecular Weight | 185.694 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(N)CC1=CC=CC=C1
InChI
InChIKey=NCAIGTHBQTXTLR-UHFFFAOYSA-N
InChI=1S/C10H15N.ClH/c1-10(2,11)8-9-6-4-3-5-7-9;/h3-7H,8,11H2,1-2H3;1H
Molecular Formula | C10H15N |
Molecular Weight | 149.2328 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00191Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html
Sources: http://www.drugbank.ca/drugs/DB00191
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/phentermine.html
Phentermine is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. The drug seems to inhibit reuptake of noradrenaline, dopamine, and seratonin through inhibition or reversal of the reuptake transporters. It may also inhibit MAO enzymes leaving more neurotransmitter available at the synapse. Phentermine (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that phentermine can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage. Phentermine is indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction. Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL238 Sources: http://www.drugbank.ca/drugs/DB00191 |
0.31 µM [EC50] | ||
Target ID: CHEMBL1951 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11911838 |
498.0 µM [Ki] | ||
Target ID: CHEMBL2039 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11911838 |
375.0 µM [Ki] | ||
Target ID: CHEMBL222 Sources: http://www.drugbank.ca/drugs/DB00191 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ADIPEX-P Approved UseADIPEX-P® is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors Launch Date-3.47241611E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
44.78 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
49.1 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2057.33 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2000 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.63 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25668796 |
7.5 mg single, oral dose: 7.5 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
20 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82.5% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: TOPIRAMATE |
PHENTERMINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Other AEs: Abdominal pain, Dizziness... Other AEs: Abdominal pain (6%) Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12Dizziness (6%) Early satiety (6%) Intermittent headache (6%) Nausea (6%) Swollen lips (6%) Upper respiratory infection (6%) |
37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Other AEs: Anorexia, Back pain... Other AEs: Anorexia (6%) Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12Back pain (6%) Chapped lips (6%) Dry skin (6%) Dyspepsia (6%) Early satiety (6%) Irregular pulse (6%) Nausea (6%) |
390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
Other AEs: Tachycardia, Hypertension... Other AEs: Tachycardia Sources: Hypertension Visual disorders NEC Nausea Insomnia Anxiety |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Disc. AE: Amnesia, Judgement impaired... Other AEs: Disorder sleep, Depression... AEs leading to discontinuation/dose reduction: Amnesia (0.3%) Other AEs:Judgement impaired (0.3%) Memory impairment (0.3%) Paraesthesia (0.3%) Depression (1%) Anxiety (0.3%) Vision blurred (0.3%) Eye pain (0.3%) Abdominal pain (0.3%) Tuberculosis skin test positive (0.3%) Nephrolithiasis (0.3%) Disorder sleep (12.9%) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105Depression (8.1%) Anxiety (9.5%) Cardiac arrhythmia (4.1%) Ischemic heart disease (1%) Disturbance in attention (3.1%) Memory impairment (2%) Cognitive disorders (1.4%) Language disorder (0.3%) Ocular disorders NEC (4.1%) Dyskinesias and movement disorders NEC (1.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Dizziness | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Early satiety | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Intermittent headache | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Nausea | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Swollen lips | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Upper respiratory infection | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Anorexia | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Back pain | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Chapped lips | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Dry skin | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Dyspepsia | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Early satiety | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Irregular pulse | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Nausea | 6% | 37.5 mg 1 times / day single, oral Recommended Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
healthy, 18 - 45 years old n = 17 Health Status: healthy Age Group: 18 - 45 years old Sex: M+F Population Size: 17 Sources: Page: nda/2012/202088Orig2s000MedR.pdf - p.12 |
Anxiety | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Hypertension | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Insomnia | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Nausea | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Tachycardia | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Visual disorders NEC | 390 mg 1 times / day single, oral Studied dose Dose: 390 mg, 1 times / day Route: oral Route: single Dose: 390 mg, 1 times / day Sources: |
healthy, mean age 30 years n = 2 Health Status: healthy Age Group: mean age 30 years Sex: M+F Population Size: 2 Sources: |
|
Language disorder | 0.3% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Abdominal pain | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Amnesia | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Anxiety | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Eye pain | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Judgement impaired | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Memory impairment | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Nephrolithiasis | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Paraesthesia | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Tuberculosis skin test positive | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Vision blurred | 0.3% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Ischemic heart disease | 1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Depression | 1% Disc. AE |
15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Cognitive disorders | 1.4% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Dyskinesias and movement disorders NEC | 1.4% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Disorder sleep | 12.9% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Memory impairment | 2% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Disturbance in attention | 3.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Cardiac arrhythmia | 4.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Ocular disorders NEC | 4.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Depression | 8.1% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Anxiety | 9.5% | 15 mg 1 times / day multiple, oral Recommended Dose: 15 mg, 1 times / day Route: oral Route: multiple Dose: 15 mg, 1 times / day Co-administed with:: topiramate(92 mg; 1/day) Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
unhealthy, mean age 51.9 years n = 295 Health Status: unhealthy Condition: obesity Age Group: mean age 51.9 years Sex: M+F Population Size: 295 Sources: Page: nda/2012/022580Orig1s000MedR.pdf - p.105 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=17 Page: 17.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39.0 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39,38 |
major | weak (co-administration study) Comment: In the presence of topiramate, phentermine Cmax and AUC0-inf increased 13 and 42%, respectively Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022580Orig1s000ClinPharmR.pdf#page=39 Page: 39,38 |
PubMed
Title | Date | PubMed |
---|---|---|
Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. | 1999 Dec |
|
Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. | 1999 Dec 1 |
|
Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. | 1999 Jul |
|
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension. | 1999 Jun |
|
Pharmaceutical cost savings of treating obesity with weight loss medications. | 1999 Nov |
|
Histologic changes in three explanted native cardiac valves following use of fenfluramines. | 1999 Sep-Oct |
|
Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. | 2000 Apr 5 |
|
[Obesity: principles of drug therapy]. | 2000 Aug |
|
Complex vascular lesions at autopsy in a patient with phentermine-fenfluramin. | 2000 Jun |
|
Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. | 2000 May 2 |
|
Silver lining to the cloud over anorexogen-related cardiac valvulopathy? | 2001 Feb 20 |
|
Pharmacologic options for the treatment of obesity. | 2001 Jul 15 |
|
A comparison of cocaine, GBR 12909, and phentermine self-administration by rhesus monkeys on a progressive-ratio schedule. | 2001 Mar 1 |
|
Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine--a case report. | 2001 May |
|
Fenfluramine and phentermine. | 2001 Nov 6 |
|
Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. | 2001 Nov-Dec |
|
Drug treatment of obesity. | 2001 Oct |
|
High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label. | 2001 Oct |
|
Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. | 2001 Oct 24-31 |
|
Acute anorectic effect of single and combined drugs in mice using a non-deprivation protocol. | 2001 Sep |
|
Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5. | 2001 Sep |
|
Pharmacotherapy of obesity: currently marketed and upcoming agents. | 2002 |
|
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. | 2002 |
|
Fen-Phen-noumenon: A mass tort litigation and settlement about to come and go. | 2002 Aug |
|
Appetite suppressants and valvular heart disease - a systematic review. | 2002 Aug 23 |
|
Morphology of anorexigen-associated valve disease by transthoracic and transesophageal echocardiography. | 2002 Dec 1 |
|
[Syncope - a systematic overview of classification, pathogenesis, diagnosis and management]. | 2002 Feb |
|
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. | 2002 Jun 7 |
|
I have tried everything I can think of to lose weight on my own and am now thinking of using weight-loss medications. Are they safe? | 2002 May |
|
Prevalence of drug use in commercial tractor-trailer drivers. | 2002 May |
|
Noradrenergic modulation of ephedrine-induced hypophagia. | 2003 Apr |
|
Obesity. | 2003 Dec |
|
Medical monitoring for pharmaceutical injuries: tort law for the public's health? | 2003 Feb 19 |
|
Obesity drug pipeline not so fat. | 2003 Feb 7 |
|
Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats. | 2003 Jul 5 |
|
Risk of valvular heart disease associated with use of fenfluramine. | 2003 Jun 11 |
|
Malpractice. Conviction upheld for doctor who treated AIDS with fen/phen. | 2003 May 9 |
|
The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment. | 2004 Dec |
|
Beneficial effects of weight loss on plasma apolipoproteins in postmenopausal women. | 2004 Dec |
|
Going before disciplinary board without counsel is unwise. Case on point: Slone-Vasquez v. Kentucky Board Of Nursing, 2003 WL 22976179 S.W.3d-KY. | 2004 Jan |
|
Pharmacological and surgical treatment of obesity. | 2004 Jul |
|
Taking things to heart. | 2004 Jul |
|
Obesity. | 2004 Jun |
|
The long-term management of obesity with continuing pharmacotherapy. | 2004 Nov |
|
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. | 2005 Jan 25 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/phentermine.html
Usual Adult Dose for Weight Loss
15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Usual Pediatric Dose for Weight Loss
17 years or older:
15 to 37.5 mg orally once a day before breakfast or 1 to 2 hours after breakfast.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10799660
Phentermine inhibited serotonin-metabolizing (MAO-A) activity in rat lung, brain, and liver with K(i) values of 85-88 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:12:44 UTC 2022
by
admin
on
Fri Dec 16 16:12:44 UTC 2022
|
Record UNII |
0K2I505OTV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29728
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
||
|
DEA NO. |
1640
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1574
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
DBSALT000138
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
M8644
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | Merck Index | ||
|
0K2I505OTV
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
0K2I505OTV
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
DTXSID20152550
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
82078
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | RxNorm | ||
|
C29361
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
1528501
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
70969
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
44090
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
50506
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
214-821-9
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
1197-21-3
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY | |||
|
SUB03767MIG
Created by
admin on Fri Dec 16 16:12:44 UTC 2022 , Edited by admin on Fri Dec 16 16:12:44 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |